Treatment for vaginal atrophy in post-menopausal women using CO2 laser
Efficacy of Fractional CO2 Laser Treatment in Post-Menopausal Women With Vaginal Atrophy
This study is testing if a CO2 laser treatment can help relieve symptoms of vaginal atrophy in post-menopausal women.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 45 Years to 65 Years |
| Sex | Female |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06726746 on ClinicalTrials.gov |
What this trial studies
This study investigates the efficacy of fractional CO2 laser treatment for alleviating symptoms of vaginal atrophy in post-menopausal women. It involves a prospective design with 30 participants who will attend four visits over a 12-week period. During the first three visits, participants will receive laser interventions, while the final visit will assess their satisfaction and any adverse events. The study will also evaluate changes in vaginal health and sexual function through standardized questionnaires and pelvic examinations.
Who should consider this trial
Good fit: Ideal candidates are sexually active post-menopausal women aged 45 to 65 experiencing symptoms of vaginal atrophy.
Not a fit: Patients with recent hormonal therapy, active infections, or serious chronic conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life and sexual health for post-menopausal women suffering from vaginal atrophy.
How similar studies have performed: Other studies have shown promising results with laser treatments for similar conditions, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Menopausal women whose ages ranged from 45 to 65 years. 2. Sexually active 3. Had symptoms of VVA (vaginal dryness, irritation, soreness, or dyspareunia) Exclusion Criteria: 1. Any history of hormonal therapy within the past 6 months 2. Vaginal moisturizer or lubricant applications within the past 30 days 3. Acute/recurrent urinary tract infection 4. Active genital infection 5. Prolapse stage II or more based on examination 6. Psychiatric disorders 7. Undiagnosed vaginal bleeding 8. Any serious disease or chronic condition that could interfere with study compliance
Where this trial is running
Cairo
- Cairo University — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Daniel Onsi
- Email: daniel.onsi@ngu.edu.eg
- Phone: +201272755335
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.